Dr. Amin J. Mirhadi, MD

Dr. Mirhadi practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Mirhadi's NPI, 1336179563, was assigned on July 4, 2006. Dr. Mirhadi graduated from UC Irvine School of Medicine in 2001. Dr. Mirhadi's California license number on file is A80890.

Dr. Mirhadi's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Mirhadi's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. Dr. Mirhadi is also affiliated with Huntington Hospital. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Mirhadi to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mirhadi practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Mirhadi's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Mirhadi is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Mirhadi's licenses on file in 2 states: California and Texas.

Dmand AI lists bone cancer radiation, brain cancer radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Mirhadi treats.

CMS data shows 3,248 Medicare services from Dr. Mirhadi across 18 procedure codes in 2024, for 263 Medicare patients. Medicare paid $338,871 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 263 Medicare patients who saw Dr. Mirhadi in 2024. The largest group is 65 to 74, with 113 patients. 75% of them have cancer, and 75% have high blood pressure. 29% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mirhadi's median patient age at 72, with 74% women.

In 2024, Dr. Mirhadi wrote 34 Medicare Part D claims. 97% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $82 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Mirhadi for performance year 2024, reported as part of a group. Dr. Mirhadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mirhadi as offering telehealth.

Dmand AI links 20 papers to Dr. Mirhadi, published from 2015 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Lung Neoplasms, Radiotherapy Dosage and Breast Neoplasms. Dr. Mirhadi has published most often in Brachytherapy. Dr. Mirhadi's most frequent co-authors are Howard M. Sandler, MD, Mitchell Kamrava, MD and Katelyn Mae Atkins, MD.

Dmand AI links Dr. Mirhadi to 5 clinical trials, 3 of them phase 1/2 studies. 3 are still active or recruiting. Conditions studied include Brain Neoplasms, Cardiotoxicity and Spinal Cord Neoplasms. Cedars-Sinai Medical Center sponsors the most, 2.

CMS Open Payments shows 5 general payments to Dr. Mirhadi from 3 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 90% of the total. Varian Medical Systems, Inc. paid the most, $2,250.

Dr. Mirhadi graduated from UC Irvine School of Medicine in 2001.

Dr. Mirhadi is in network with 13 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.